blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2655408

EP2655408 - ROBO1-FC FUSION PROTEIN FOR USE IN THE TREATMENT OF HEPATOCARCINOMA [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  12.05.2017
Database last updated on 02.11.2024
Most recent event   Tooltip12.10.2018Lapse of the patent in a contracting state
New state(s): AL		published on 14.11.2018  [2018/46]
Applicant(s)For all designated states
Sanofi
174 avenue de France
75013 Paris / FR
[2016/27]
Former [2013/44]For all designated states
Sanofi
174 avenue de France
75013 Paris / FR
Inventor(s)01 / DOL-GLEIZES, Frédérique
c/o Sanofi
Département Brevets
174 avenue de France
75013 Paris / FR
02 / GUEGUEN-DORBES, Geneviève
c/o Sanofi
Département Brevets
174 avenue de France
75013 Paris / FR
 [2016/27]
Former [2013/44]01 / DOL-GLEIZES, Frédérique
c/o Sanofi
Département Brevets
174 avenue de France
F-75013 Paris / FR
02 / GUEGUEN-DORBES, Geneviève
c/o Sanofi
Département Brevets
174 avenue de France
F-75013 Paris / FR
Representative(s)Lavoix
2, place d'Estienne d'Orves
75441 Paris Cedex 09 / FR
[N/P]
Former [2016/27]Jan, Gaëlle
Cabinet Lavoix
2, place d'Estienne d'Orves
75441 Paris Cedex 09 / FR
Former [2013/44]Martin-Touaux, Elsa, et al
Sanofi
Département Brevets
54, rue La Boétie
75008 Paris / FR
Application number, filing date11802949.522.12.2011
[2016/27]
WO2011EP73739
Priority number, dateFR2010006116323.12.2010         Original published format: FR 1061163
EP2011030633614.10.2011         Original published format: EP 11306336
[2013/44]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2012085178
Date:28.06.2012
Language:EN
[2012/26]
Type: A1 Application with search report 
No.:EP2655408
Date:30.10.2013
Language:EN
The application published by WIPO in one of the EPO official languages on 28.06.2012 takes the place of the publication of the European patent application.
[2013/44]
Type: B1 Patent specification 
No.:EP2655408
Date:06.07.2016
Language:EN
[2016/27]
Search report(s)International search report - published on:EP28.06.2012
ClassificationIPC:C07K14/475, A61K38/18
[2013/44]
CPC:
A61P1/18 (EP); C07K19/00 (KR); C07K14/70503 (EP,CN,US);
C07K16/28 (US); A61K38/18 (KR); A61P35/00 (EP);
C07K14/475 (KR); A61K38/00 (EP,CN,US); C07K2319/30 (EP,CN,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2013/44]
Extension statesBA23.07.2013
ME23.07.2013
TitleGerman:ROBO1-FC-FUSIONSPROTEIN ZUR VERWENDUNG BEI DER BEHANDLUNG VON LEBERKARZINOM[2013/44]
English:ROBO1-FC FUSION PROTEIN FOR USE IN THE TREATMENT OF HEPATOCARCINOMA[2013/44]
French:PROTÉINE HYBRIDES ROBO1-FC À UTILISER DANS TRAITEMENT D' HÉPATOCARCINOMES[2016/08]
Former [2013/44]PROTÉINE HYBRIDES ROBO1-FC À UTILISER DANS TRAITEMENT D'HÉPATOCARCINOMES
Entry into regional phase23.07.2013National basic fee paid 
23.07.2013Designation fee(s) paid 
23.07.2013Examination fee paid 
Examination procedure23.07.2013Examination requested  [2013/44]
12.02.2014Amendment by applicant (claims and/or description)
08.04.2015Despatch of a communication from the examining division (Time limit: M02)
01.06.2015Reply to a communication from the examining division
28.01.2016Communication of intention to grant the patent
27.05.2016Fee for grant paid
27.05.2016Fee for publishing/printing paid
27.05.2016Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  08.04.2015
Opposition(s)07.04.2017No opposition filed within time limit [2017/24]
Fees paidRenewal fee
12.12.2013Renewal fee patent year 03
11.12.2014Renewal fee patent year 04
10.12.2015Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU22.12.2011
AL06.07.2016
AT06.07.2016
BE06.07.2016
CY06.07.2016
CZ06.07.2016
DK06.07.2016
EE06.07.2016
ES06.07.2016
FI06.07.2016
HR06.07.2016
IT06.07.2016
LT06.07.2016
LV06.07.2016
MC06.07.2016
MK06.07.2016
NL06.07.2016
PL06.07.2016
RO06.07.2016
RS06.07.2016
SE06.07.2016
SI06.07.2016
SK06.07.2016
SM06.07.2016
TR06.07.2016
BG06.10.2016
NO06.10.2016
GR07.10.2016
IS06.11.2016
PT07.11.2016
GB22.12.2016
IE22.12.2016
LU22.12.2016
MT22.12.2016
CH31.12.2016
LI31.12.2016
FR02.01.2017
[2018/46]
Former [2018/45]HU22.12.2011
AT06.07.2016
BE06.07.2016
CY06.07.2016
CZ06.07.2016
DK06.07.2016
EE06.07.2016
ES06.07.2016
FI06.07.2016
HR06.07.2016
IT06.07.2016
LT06.07.2016
LV06.07.2016
MC06.07.2016
MK06.07.2016
NL06.07.2016
PL06.07.2016
RO06.07.2016
RS06.07.2016
SE06.07.2016
SI06.07.2016
SK06.07.2016
SM06.07.2016
TR06.07.2016
BG06.10.2016
NO06.10.2016
GR07.10.2016
IS06.11.2016
PT07.11.2016
GB22.12.2016
IE22.12.2016
LU22.12.2016
MT22.12.2016
CH31.12.2016
LI31.12.2016
FR02.01.2017
Former [2018/43]HU22.12.2011
AT06.07.2016
BE06.07.2016
CY06.07.2016
CZ06.07.2016
DK06.07.2016
EE06.07.2016
ES06.07.2016
FI06.07.2016
HR06.07.2016
IT06.07.2016
LT06.07.2016
LV06.07.2016
MC06.07.2016
MK06.07.2016
NL06.07.2016
PL06.07.2016
RO06.07.2016
RS06.07.2016
SE06.07.2016
SI06.07.2016
SK06.07.2016
SM06.07.2016
BG06.10.2016
NO06.10.2016
GR07.10.2016
IS06.11.2016
PT07.11.2016
GB22.12.2016
IE22.12.2016
LU22.12.2016
MT22.12.2016
CH31.12.2016
LI31.12.2016
FR02.01.2017
Former [2018/28]HU22.12.2011
AT06.07.2016
BE06.07.2016
CY06.07.2016
CZ06.07.2016
DK06.07.2016
EE06.07.2016
ES06.07.2016
FI06.07.2016
HR06.07.2016
IT06.07.2016
LT06.07.2016
LV06.07.2016
MC06.07.2016
MK06.07.2016
NL06.07.2016
PL06.07.2016
RO06.07.2016
RS06.07.2016
SE06.07.2016
SI06.07.2016
SK06.07.2016
SM06.07.2016
BG06.10.2016
NO06.10.2016
GR07.10.2016
IS06.11.2016
PT07.11.2016
GB22.12.2016
IE22.12.2016
LU22.12.2016
CH31.12.2016
LI31.12.2016
FR02.01.2017
Former [2017/51]AT06.07.2016
BE06.07.2016
CZ06.07.2016
DK06.07.2016
EE06.07.2016
ES06.07.2016
FI06.07.2016
HR06.07.2016
IT06.07.2016
LT06.07.2016
LV06.07.2016
MC06.07.2016
NL06.07.2016
PL06.07.2016
RO06.07.2016
RS06.07.2016
SE06.07.2016
SI06.07.2016
SK06.07.2016
SM06.07.2016
BG06.10.2016
NO06.10.2016
GR07.10.2016
IS06.11.2016
PT07.11.2016
GB22.12.2016
IE22.12.2016
LU22.12.2016
CH31.12.2016
LI31.12.2016
FR02.01.2017
Former [2017/50]AT06.07.2016
BE06.07.2016
CZ06.07.2016
DK06.07.2016
EE06.07.2016
ES06.07.2016
FI06.07.2016
HR06.07.2016
IT06.07.2016
LT06.07.2016
LV06.07.2016
MC06.07.2016
NL06.07.2016
PL06.07.2016
RO06.07.2016
RS06.07.2016
SE06.07.2016
SI06.07.2016
SK06.07.2016
SM06.07.2016
BG06.10.2016
NO06.10.2016
GR07.10.2016
IS06.11.2016
PT07.11.2016
IE22.12.2016
LU22.12.2016
CH31.12.2016
LI31.12.2016
FR02.01.2017
Former [2017/49]AT06.07.2016
BE06.07.2016
CZ06.07.2016
DK06.07.2016
EE06.07.2016
ES06.07.2016
FI06.07.2016
HR06.07.2016
IT06.07.2016
LT06.07.2016
LV06.07.2016
MC06.07.2016
NL06.07.2016
PL06.07.2016
RO06.07.2016
RS06.07.2016
SE06.07.2016
SI06.07.2016
SK06.07.2016
SM06.07.2016
BG06.10.2016
NO06.10.2016
GR07.10.2016
IS06.11.2016
PT07.11.2016
IE22.12.2016
LU22.12.2016
CH31.12.2016
LI31.12.2016
FR02.01.2017
Former [2017/45]AT06.07.2016
BE06.07.2016
CZ06.07.2016
DK06.07.2016
EE06.07.2016
ES06.07.2016
FI06.07.2016
HR06.07.2016
IT06.07.2016
LT06.07.2016
LV06.07.2016
MC06.07.2016
NL06.07.2016
PL06.07.2016
RO06.07.2016
RS06.07.2016
SE06.07.2016
SI06.07.2016
SK06.07.2016
SM06.07.2016
BG06.10.2016
NO06.10.2016
GR07.10.2016
IS06.11.2016
PT07.11.2016
Former [2017/37]AT06.07.2016
BE06.07.2016
CZ06.07.2016
DK06.07.2016
EE06.07.2016
ES06.07.2016
FI06.07.2016
HR06.07.2016
IT06.07.2016
LT06.07.2016
LV06.07.2016
NL06.07.2016
PL06.07.2016
RO06.07.2016
RS06.07.2016
SE06.07.2016
SI06.07.2016
SK06.07.2016
SM06.07.2016
BG06.10.2016
NO06.10.2016
GR07.10.2016
IS06.11.2016
PT07.11.2016
Former [2017/31]AT06.07.2016
BE06.07.2016
CZ06.07.2016
DK06.07.2016
EE06.07.2016
ES06.07.2016
FI06.07.2016
HR06.07.2016
IT06.07.2016
LT06.07.2016
LV06.07.2016
NL06.07.2016
PL06.07.2016
RO06.07.2016
RS06.07.2016
SE06.07.2016
SK06.07.2016
SM06.07.2016
BG06.10.2016
NO06.10.2016
GR07.10.2016
IS06.11.2016
PT07.11.2016
Former [2017/13]AT06.07.2016
BE06.07.2016
ES06.07.2016
FI06.07.2016
HR06.07.2016
IT06.07.2016
LT06.07.2016
LV06.07.2016
NL06.07.2016
PL06.07.2016
RS06.07.2016
SE06.07.2016
NO06.10.2016
GR07.10.2016
IS06.11.2016
PT07.11.2016
Former [2017/11]AT06.07.2016
BE06.07.2016
ES06.07.2016
FI06.07.2016
HR06.07.2016
IT06.07.2016
LT06.07.2016
NL06.07.2016
PL06.07.2016
RS06.07.2016
SE06.07.2016
NO06.10.2016
GR07.10.2016
IS06.11.2016
PT07.11.2016
Former [2017/10]BE06.07.2016
FI06.07.2016
HR06.07.2016
IT06.07.2016
LT06.07.2016
NL06.07.2016
PL06.07.2016
RS06.07.2016
SE06.07.2016
NO06.10.2016
IS06.11.2016
Former [2017/09]FI06.07.2016
IT06.07.2016
LT06.07.2016
NL06.07.2016
NO06.10.2016
Former [2017/07]LT06.07.2016
Cited inInternational search[XY]WO03075860  (ABGENT INC [US]) [X] 1-6,10 * claims 1-29 * [Y] 6-9,11;
 [XP]WO2011134420  (SHANGHAI INST BIOL SCIENCES [CN], et al) [XP] 1-7,10,11 * figures 6,7; claims 1-27 *;
 [Y]EP1744162  (ABURATANI HIROYUKI [JP], et al) [Y] 1-6,10,11 * paragraph [0023]; example 12; claims 1-35; sequence 11 *;
 [Y]WO2008134046  (GENENTECH INC [US], et al) [Y] 8,9 * paragraph [0149] * * paragraph [0224]; figure 1c; claims 4,10,20,21,23,33 *;
 [Y]WO9920764  (UNIV CALIFORNIA [US]) [Y] 8,9 * page 4, paragraph 3 * * page 21, paragraph 3; figure 2 *;
 [Y]  - LIU ZHE ET AL, "Extracellular Ig domains 1 and 2 of Robo are important for ligand (Slit) binding", MOLECULAR AND CELLULAR NEUROSCIENCES, SAN DIEGO, US, vol. 26, no. 2, doi:10.1016/J.MCN.2004.01.002, ISSN 1044-7431, (20040601), pages 232 - 240, (20040416), XP002605466 [Y] 6-9,11 * abstract *

DOI:   http://dx.doi.org/10.1016/J.MCN.2004.01.002
 [Y]  - HIVERT BRUNO ET AL, "Robo1 and Robo2 are homophilic binding molecules that promote axonal growth", MOLECULAR AND CELLULAR NEUROSCIENCES, SAN DIEGO, US, (20021201), vol. 21, no. 4, doi:10.1006/MCNE.2002.1193, ISSN 1044-7431, pages 534 - 545, XP002605467 [Y] 6-9,11 * abstract * * page 538 * * page 542; figure 7 *

DOI:   http://dx.doi.org/10.1006/MCNE.2002.1193
 [Y]  - XIAN JIAN ET AL, "Targeted disruption of the 3p12 gene, Dutt1/Robo1, predisposes mice to lung adenocarcinomas and lymphomas with methylation of the gene promoter", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (20040915), vol. 64, no. 18, ISSN 0008-5472, pages 6432 - 6437, XP002605471 [Y] 1-6,10,11 * abstract *
 [A]  - HANNULA-JOUPPI KATARIINA ET AL, "The axon guidance receptor gene ROBO1 is a candidate gene for developmental dyslexia.", PLOS GENETICS, (200510), vol. 1, no. 4, ISSN 1553-7404, pages 0467 - 0474, XP002675582 [A] 1-6,10,11 * abstract * * page 0472, column l, paragraph 1 *

DOI:   http://dx.doi.org/10.1371/journal.pgen.0010050
 [A]  - DALLOL ASHRAF ET AL, "Tumour specific promoter region methylation of the human homologue of the Drosophila Roundabout gene DUTT1 (ROBO1) in human cancers.", ONCOGENE, (20020502), vol. 21, no. 19, ISSN 0950-9232, pages 3020 - 3028, XP002675583 [A] 1-6,10,11 * abstract *

DOI:   http://dx.doi.org/10.1038/SJ/ONC/1205421
 [A]  - GRÖNE JÖRN ET AL, "Robo1/Robo4: differential expression of angiogenic markers in colorectal cancer.", ONCOLOGY REPORTS, (200606), vol. 15, no. 6, ISSN 1021-335X, pages 1437 - 1443, XP002675584 [A] 1-6,10,11 * abstract *

DOI:   http://dx.doi.org/10.3892/or.15.6.1437
 [A]  - WANG LI-JING ET AL, "Targeting Slit-Roundabout signaling inhibits tumor angiogenesis in chemical-induced squamous cell carcinogenesis.", CANCER SCIENCE, (200803), vol. 99, no. 3, ISSN 1349-7006, pages 510 - 517, XP002675585 [A] 1-6,10,11 * abstract *

DOI:   http://dx.doi.org/10.1111/J.1349-7006.2007.00721.X
 [A]  - CLARK K ET AL, "Temporal and spatial expression of two isoforms of the Dutt1/Robo1 gene in mouse development", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, (20020717), vol. 523, no. 1-3, doi:10.1016/S0014-5793(02)02904-6, ISSN 0014-5793, pages 12 - 16, XP004371138 [A] 1-6,10,11 * abstract *

DOI:   http://dx.doi.org/10.1016/S0014-5793(02)02904-6
 [A]  - NURAL HIKMET FEYZA ET AL, "The Slit receptor Robo1 is predominantly expressed via the Dutt1 alternative promoter in pioneer neurons in the embryonic mouse brain and spinal cord", GENE EXPRESSION PATTERNS, ELSEVIER, (20071001), vol. 7, no. 8, doi:10.1016/J.MODGEP.2007.07.004, ISSN 1567-133X, pages 837 - 845, XP002605468 [A] 1,6,7,13 * abstract *

DOI:   http://dx.doi.org/10.1016/J.MODGEP.2007.07.004
 [A]  - KIDD T ET AL, "RecName: Full=Roundabout homolog 1; AltName: Full=Deleted in U twenty twenty; AltName: Full=H-Robo-1; Flags: Precursor", UniProt, (19980101), Database accession no. Q9Y6N7, XP002605469 [A] 1-6,10,11 * the whole document *
 [A]  - MORLOT CECILE ET AL, "Structural insights into the Slit-Robo complex", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, WASHINGTON, DC; US, (20070918), vol. 104, no. 38, doi:10.1073//ONAS.0705310104, ISSN 0027-8424, pages 14923 - 14928, XP002605470 [A] 1-6,10,11 * abstract *

DOI:   http://dx.doi.org/10.1073//ONAS.0705310104
 [A]  - WANG B ET AL, "Induction of tumor angiogenesis by Slit-Robo signaling and inhibition of cancer growth by blocking Robo activity", CANCER CELL, CELL PRESS, US, (20030701), vol. 4, no. 1, doi:10.1016/S1535-6108(03)00164-8, ISSN 1535-6108, pages 19 - 29, XP002996193 [A] 1-6,10,11 * abstract *

DOI:   http://dx.doi.org/10.1016/S1535-6108(03)00164-8
by applicantWO03075860
 WO2008065543
 WO9709351
    - JONES C.A. ET AL., NAT. MED, (2008), vol. 14, pages 448 - 453
    - STELLA MC ET AL., MOL BIOL CELL., (2009), vol. 20, no. 2, pages 642 - 657
    - WANG ET AL., CANCER SCI., (200803), vol. 99, no. 3, pages 510 - 7
    - LATIL ET AL., INT J CANCER., (20030120), vol. 103, no. 3, pages 306 - 15
    - WANG ET AL., CANCER CELL, (200307), vol. 4, no. 1, pages 19 - 29
    - AVCI ET AL., BMC CANCER, (2008), vol. 8, page 392
    - SHEN ET AL., AJP, (2009), vol. 175, no. 2, page 479
    - LIU ET AL., MOL. CELL NEUROSCI, (2004), vol. 26, pages 232 - 240
    - ANGLA ET AL., MOL. IMMUNOL., (1993), vol. 30, pages 105 - 108
    - SADDIC ET AL., METHODS MOL. BIOL., (2002), vol. 194, pages 23 - 36
    - ANUMULA ET AL., GLYCOBIOLOGY, (1998), vol. 8, pages 685 - 694
    - FUKUHARA, N. ET AL., J. BIOL. CHEM., (2008), vol. 283, pages 16226 - 16234
    - CANZIANI ET AL., ANAL. BIOCHEM., (2004), vol. 325, pages 301 - 307
    - FIMUS ET AL., MOL DIAGN, (2004), vol. 8, no. 4, pages 207 - 12
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.